AGARWALEYE Dr. Agarwal's Health Care Q3 FY26 results (Oct–Dec 2025) and concall
Dr. Agarwal's Health Care Limited delivered a robust Q3 and 9M FY26 performance, marked by strong revenue and EBITDA growth, significant PAT expansion, and healthy margin improvement. The company continued its aggressive network expansion, commissioning 14 new Greenfield facilities, and saw strong growth in high-end and robotic surgeries. While the refractive segment experienced some slowdown, management expressed confidence in its operational efficiency, same-store sales growth, and ability to meet full-year guidance, despite rising employee costs and regional challenges.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue up 25.0%, net profit up 75.0% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 255 | 268 | 281 | 302 | 309 +21% | 335 +25% |
| EBITDA | 58 | 65 | 73 | 67 | 69 +19% | 80 +23% |
| Net profit | -4 | 8 | 27 | 10 | 5 +225% | 14 +75% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
